Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 244-252

  Sanchez Martin M ^a   Pandiella, A ^a  

^a CSIC   (Spain)

Author keywords

breast cancer; HER; tyrosine kinase inhibitors

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LACTATE DEHYDROGENASE; LAPATINIB; NERATINIB; PELITINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIMERIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; FORSTER RESONANCE ENERGY TRANSFER ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR HETERODIMERIZATION; WESTERN BLOTTING;

AMINOQUINOLINES; ANILINE COMPOUNDS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MORPHOLINES; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84860216901     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26358     Document Type: Article

References (33)

1. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
2. Holbro T, Civenni G, Hynes NE,. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
4. Vivanco I, Mellinghoff IK,. Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010; 22: 573-8.
5. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763-73.
6. Lemmon MA,. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315: 638-48.
7. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S,. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541-52.
8. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J,. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137: 1293-307.
9. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G,. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009; 34: 641-51.
10. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW,. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495-505.
11. Baselga J, Arteaga CL,. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-59.
12. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A,. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50: 1550-8.
13. Altundag K, Esteva FJ, Arun B,. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anticancer Agents 2005; 5: 99-106.
14. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007; 25: 675-81.
15. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX,. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-37.
16. Yaish P, Gazit A, Gilon C, Levitzki A,. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242: 933-5.
17. Noonberg SB, Benz CC,. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000; 59: 753-67.
18. Zhang J, Yang PL, Gray NS,. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
19. Fry DW,. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 2000; 15: 3-16.
20. Wakeling AE,. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2002; 2: 382-7.
21. Cabrera N, Diaz-Rodriguez E, Becker E, Martin-Zanca D, Pandiella A,. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol 1996; 132: 427-36.
22. Seoane S, Montero JC, Ocana A, Pandiella A,. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 2010; 102: 1432-46.
23. Snapp EL, Hegde RS,. Rational design and evaluation of FRET experiments to measure protein proximities in cells. Curr Protoc Cell Biol 2006; Chapter 17:Unit 17 9.
24. de Alava E, Ocana A, Abad M, Montero JC, Esparis-Ogando A, Rodriguez CA, Otero AP, Hernandez T, Cruz JJ, Pandiella A,. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007; 25: 2656-63.
25. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y,. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002; 21: 2407-17.
26. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J,. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28: 803-14.
27. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-9.
28. Stamos J, Sliwkowski MX, Eigenbrot C,. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-72.
29. Eck MJ, Yun CH,. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 2010; 1804: 559-66.
30. Sorkin A, Goh LK,. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314: 3093-106.
31. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
32. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A,. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 2005; 65: 6801-10.
33. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J,. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-30.